TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment.

Meng Wu,Xian Chen,Jianfang Lou,Shuping Zhang,Xiaojie Zhang,Lei Huang,Ruihong Sun,Peijun Huang,Fang Wang,Shiyang Pan
DOI: https://doi.org/10.18632/oncotarget.10003
2016-01-01
Oncotarget
Abstract:CD8(+) regulatory T cells (Tregs) contribute to cancer progression and immune evasion. We previously reported that CD8(+) Tregs could be induced in vitro by co-culture of CD8(+) T cells with the OC cell lines SKOV3/A2780. Here, we described the role of TGF-beta 1 in CD8(+) Treg induction by the OC microenvironment. OC patients expressed high levels of TGF-beta 1, as did the co-culture supernatant from CD8(+) T cells and SKOV3. Additionally, TGF-beta 1 levels were positively correlated with CD8(+) Treg percentages in OC. Neutralization experiments, cytokine studies and proliferation assays revealed that the in vitro-induced CD8(+) Tregs depended at least partially on up-regulated expression of TGF-beta 1 to exert their suppressive function. CD8(+) T cells cultured with SKOV3 exhibited marked activation of p38 MAPK than CD8(+) T cells cultured alone, which could be inhibited by TGF-beta 1-neutralizing antibody. Moreover, the p38 specific inhibitor SB203580 dose-dependently blocked the TGF-beta 1 activated conversion of CD8(+) T cells into CD8(+) Tregs. These data suggested that in vitro-induction of CD8(+) Tregs depended in part on TGF-beta 1 activation of p38 MAPK signaling. Therefore, p38 MAPK could be a therapeutic target in OC anti-tumor immunotherapy.
What problem does this paper attempt to address?